Eagle Pharmaceuticals Inc (EGRX)

OTC Markets
Currency in USD
3.000
+0.105(+3.63%)
Closed·
EGRX Scorecard
Full Analysis
Significant return over the last week
EGRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.3603.000
52 wk Range
0.0036.370
Key Statistics
Edit
Prev. Close
3
Open
2.36
Day's Range
2.36-3
52 wk Range
0.003-6.37
Volume
620
Average Vol. (3m)
8.27K
1-Year Change
-45.45%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EGRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

Eagle Pharmaceuticals Inc News & Analysis

Show more

Eagle Pharmaceuticals Inc Company Profile

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Employees
134

Compare EGRX to Peers and Sector

Metrics to compare
EGRX
Peers
Sector
Relationship
P/E Ratio
0.0x−4.0x−0.5x
PEG Ratio
0.000.000.00
Price / Book
0.0x2.7x2.6x
Price / LTM Sales
0.0x8.9x3.0x
Upside (Analyst Target)
0.0%174.0%49.2%
Fair Value Upside
Unlock7.1%7.4%Unlock

Earnings

Latest Release
May 30, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / 53.90M
EPS Revisions
Last 90 days

EGRX Income Statement

People Also Watch

530.28
GEV
+2.56%
48.42
HIMS
+0.92%
45.69
CELH
-1.87%
47.11
SMCI
-2.99%
80.90
MRK
-0.04%

FAQ

What Is the Eagle Pharm (EGRX) Stock Price Today?

The Eagle Pharm stock price today is 3.00

What Stock Exchange Does Eagle Pharm Trade On?

Eagle Pharm is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Eagle Pharm?

The stock symbol for Eagle Pharm is "EGRX."

What Is the Eagle Pharm Market Cap?

As of today, Eagle Pharm market cap is 39.07M.

What Is Eagle Pharm's Earnings Per Share (TTM)?

The Eagle Pharm EPS (TTM) is 0.91.

When Is the Next Eagle Pharm Earnings Date?

Eagle Pharm will release its next earnings report on Aug 05, 2025.

From a Technical Analysis Perspective, Is EGRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Eagle Pharm Stock Split?

Eagle Pharm has split 0 times.

How Many Employees Does Eagle Pharm Have?

Eagle Pharm has 134 employees.

What is the current trading status of Eagle Pharm (EGRX)?

As of Jul 08, 2025, Eagle Pharm (EGRX) is trading at a price of 3.00, with a previous close of 3.00. The stock has fluctuated within a day range of 2.36 to 3.00, while its 52-week range spans from 0.00 to 6.37.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.